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ABSTRACT  
Objective: A stability-indicating high performance liquid chromatographic (HPLC) method was developed and validated for the estimation of 
combined tablet formulation of valsartan and sacubitril. 
Methods: Chromatographic separation was optimized by gradient HPLC on a C18 column [Xterra, 250 x 4.6 mm, 5µ] utilizing a mobile phase 
consisting acetonitrile, methanol and potassium dihydrogen phosphate, pH 3.8 in the ratio of 30: 50:20 v/v at a flow rate of 1 ml/min with UV 
detection at 263 nm.  
Results: The retention time of sacubitril and valsartan was 3.01 min and 4.22 min respectively. Good linearity obtained over the range of 20μg/ml 
to 160μg/ml for valsartan and sacubitril. The correlation coefficient was found to be 0.999and0.998 for sacubitril and valsartan respectively. The % 
RSD of precision for sacubitril and valsartan was found to be 0.31 and 0.27 respectively. The % mean recovery was found to be 99.20-99.54% for 
valsartan and 99.85-100.90% for sacubitril. The results obtained for accuracy, precision, LOD, LOQ and ruggedness were within limits.  
Conclusion: The proposed HPLC method was found to be simple, specific, precise, accurate, rapid and economical for simultaneous estimation of 
valsartan and sacubitril in bulk and tablet dosage form. Thus the validated economical method was applied for forced degradation study of 
valsartan and sacubitril tablet. 
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INTRODUCTION 
Valsartan is a nonpeptide, orally active and specific angiotensin II 
receptor blocker acting on the AT1 receptor subtype. Valsartan is 
chemically N-(1-oxopentyl)-N-[[2'-(1Htetrazol-5-yl)[1,1'-biphenyl] 
-4-yl]methyl]-Lvaline [1-5]. Methods such as HPLC [6-8], LC-MS 
[9-11], Protein precipitation [12], Capillary electrophoresis [13] 
and Simultaneous UV-spectrophotometric methods [14-15] are 
reported for estimation of valsartan alone or in combination with 
other agents. sacubitril is chemically 4-[[(2S,4R)-5-ethoxy-4-
methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-
oxobutanoic acid [16]. Sacubitril is an antihypertensive drug used 
in combination with valsartan for the treatment of heart failure. 
[17-19] Literature search reveals that only two analytical methods 
were reported for simultaneous estimation of valsartan and 
sacubitril from rat plasma using LC-MS/MS [20] and from a 
synthetic mixture using HPLC [21]. There is no stability indicating 
analytical methods were reported for simultaneous estimation of 
atovaquone and proguanil. Hence a simple, rapid, sensitive and 
accurate stability indicating HPLC method was developed for the 
simultaneous estimation of valsartan and sacubitril from bulk and 
pharmaceutical dosage form. 
 
  
Sacubitril structure from pubchem Valsartan structure from pubchem 
 
MATERIALS AND METHODS [21] 
Chemicals and reagents 
HPLC grade methanol, acetonitrile and analytical grade trifluoro 
acetic acid were purchased from Merck (Mumbai, India). Sacubitril 
and valsartan standards were received as gift samples from Manus 
Akketeva and Lupin Ltd, India, respectively. 
Instrumentation 
The HPLC system consisted of Alliance waters 2695 with dual λ 
Absorbance UV detector. HPLC column BDS 250 mm x 4.6 mm, 5µ. 
Mobile phase filtration unit (Pall Life sciences, Mumbai, India), LAB-
INDIA U. V with UV Win software, Sonicator, PH meter (LAB-INDIA), 
digital balance (Denver). 
Preparation of sample solution 
Twenty tablets each containing 24 mg of sacubitril and 26 mg of 
valsartan were weighed and powdered equivalent to dose, 
transferred to a 100 ml volumetric flask, and extracted with 
methanol. The mixture was sonicated for 20 min in an ultrasonic 
bath. The volume was adjusted to 100 ml with the same solvent and 
then filtered. Transfer 1 ml of solution into a 10 ml volumetric flask 
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and diluted up to the mark with diluents. to obtain a Final 
concentration of sacubitril and valsartan was found to be 24 and 
26μg/ml respectively.  
Chromatographic conditions 
Chromatographic Conditions the HPLC system consisted of 
Shimadzu gradient HPLC (JAPAN) with dual λ Absorbance UV 
detector. The wavelength of detection as set at 263 nm. Separation 
was carried out in isocratic mode on Xterra C18 column (4.6x250 
mmx5 µm) and the retention time of sacubitril and valsartan was 
found to be 3.01 min and 4.22 min respectively. (fig. 1), using mobile 
phase consisting acetonitrile, methanol and potassium dihydrogen 
phosphate, pH 3.8 in the ratio of 30: 50:20 v/v at a flow rate of 1 
ml/min with UV detection at 263 nm. The mobile phase filtered 
through nylon millipore (0.2 µm) membrane filter, purchased from 
pall life sciences, Mumbai and degassed with Ultrasonicator prior to 
use. Chromatography was carried out at room temperature 25 °C 
and maintains the column temperature at 32 °C. 
  
 
Fig. 1: Chromatogram of sacubitril and valsartan 
 
The developed Method was validated for linearity, precision, 
accuracy, ruggedness and is applied for forced degradation studies 
as per the ICH guidelines [22-26]. 
RESULTS AND DISCUSSION 
Method validation 
Linearity 
Linear concentrations of both drugs were prepared, and the best fit 
line was calculated. Wide range calibration was determined by 
solutions containing 20μg/ml to 160μg/ml (table 1) for valsartan and 
sacubitril. The correlation coefficient was found to be 0.999and0.998 
for sacubitril and valsartan respectively (shown in fig 2 and 3). 
Limit of detection (LOD) and limit of quantification (LOQ) 
The LOD is calculated using the formula 3.3 times σ/s where “σ” is 
the standard deviation of the intercept obtained for calibration 
curve and “s” is the slope of the calibration curve. Similarly, LOQ is 
calculated using the formula 10 times σ/s. The calculated LOD and 
LOQ are shown in table 2 and 3. 
 
Table 1: Linearity data for valsartan and sacubitril 
S. No.  Sacubitril  Valsartan 
Concentration(µg/ml) Peak area Concentration(µg/ml) Peak area 
1 20 5284 20 6041 
2 40 9728 40 10734 
3 60 14260 60 15849 
4 80 19689 80 21347 
5 100 24135 100 25761 
6 120 29541 120 31474 
7 140 34581 140 35250 
8 160 39517 160 41502 
 
 
Fig. 2: Calibration curve of sacubitril 
 
Fig. 3: Calibration curve of valsartan
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Table 2: LOD and LOQ results of sacubitril 
Conc (µg/ml)  Area 1 Area 2 Area 3 Avg area 
20 5373 5198 5281 5284 
40 9826 9613 9746 9728 
60 14119 14290 14372 14260 
80 19492 19124 20452 19689 
100 23865 23677 24865 24135 
120 29238 29148 30238 29541 
140 34611 34521 34611 34581 
160 39184 39284 40084 39517 
Intercept -18.57 -228.9 -41.57 -96.6 
slope 244.2 245.4 249.9 246.5 
Intercept standard deviation 115.36 
LOD (µg/ml) 1.54 
LOQ(µg/ml) 4.68 
 
Table 3: LOD and LOQ results of valsartan 
Conc (µg/ml)  Area 1 Area 2 Area 3 Avg Area 
20 6039 5997 6087 6041 
40 10178 11012 11013 10734 
60 15817 15675 16057 15849 
80 21156 21346 21541 21347 
100 25195 26101 25987 25761 
120 31034 31274 32114 31474 
140 35273 35192 35287 35250 
160 41312 41178 42018 41502 
Intercept 639.2 1040 968.1 882.4 
Slope 251.2 249.2 253.2 251.2 
Intercept standard deviation 213.69 
LOD (µg/ml) 2.80 
LOQ(µg/ml) 8.50 
 
Precision 
The intraday precision was demonstrated by injecting standard 
solutions of valsartan and sacubitril with 40µg/ml and 140µg/ml 
respectively as per the test procedure (table 4) and recording 
the chromatograms of six standard solutions. The % RSD of 
Sacubitril and Valsartan was found to be 0.31 and 0.27 
respectively. 
Intermediate precision 
Intermediate precision of the analytical method was determined by 
performing method precision on in three successive days by different 
analysts under same experimental condition by injecting six replicate 
standards preparations was determined and the mean % RSD of 
sacubitril (40µg/ml) and valsartan (140µg/ml) was found to be 0.31 and 
0.27 respectively (table 5). 
 
Table 4: Method precision data of valsartan and sacubitril 
S. No Sacubitril (40µg/ml) Valsartan (140µg/ml) 
Area Area 
1 9826 34987 
2 9741 35016 
3 9798 35126 
4 9814 35195 
5 9804 35203 
6 9818 35183 
Mean 9800 35118 
SD 30.64 94.87 
%RSD 0.31 0.27 
 
Table 5: Precision data for sacubitril and valsartan 
Sacubitril area for  40µg/ml  Valsartan area for  140µg/ml  
S. No. day-1 day-2 day-3 avg day-1 day-2 day-3 avg 
1 9806 9797 9787 9797 34917 34882 34847 34882 
2 9722 9712 9702 9712 34946 34911 34876 34911 
3 9778 9769 9759 9769 35056 35021 34985 35021 
4 9794 9785 9775 9785 35125 35089 35054 35089 
5 9784 9775 9765 9775 35133 35097 35062 35097 
6 9798 9789 9779 9789 35113 35077 35042 35077 
Mean 9781 9771 9761 9771 35048 35013 34978 35013 
SD 30.6 30.6 30.5 30.6 94.69 94.59 94.5 94.59 
% RSD 0.31 0.31 0.31 0.31 0.27 0.27 0.27 0.27 
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Accuracy 
Accuracy of the method was established by performing recovery 
studies according to the ICH guidelines. Spiked samples were 
prepared by spiking pre-analyzed sample solutions with the pure 
drug at three different concentration levels each in triplicate. Mean 
percentage recovery values at three different concentrations of the 
two drugs were calculated. The % mean recovery of sacubitril 
(99.20-99.54%) and valsartan (99.85-100.90. %) at each level was 
within the limits of 98% and 102% (table 6). 
 
Table 6: Accuracy of valsartan and sacubitril 
Accuracy of sacubitril 
S. N0. Conc. Calculated concn. % recovery Mean recovery SD %RSD 
1 80 79.54 99.43    
2 80 79.43 99.29 99.43 0.14 0.15 
3 80 79.66 99.58    
1 160 159.38 99.61    
2 160 158.96 99.35 99.54 0.16 0.17 
3 160 159.44 99.65    
1 240 240.05 100.02    
2 240 236.88 98.70 99.20 0.71 0.72 
3 240 237.35 98.89    
Accuracy of valsartan 
S. No. Conc. Calculated concn. % recovery Mean recovery SD %RSD 
1 80 80.45 100.56       
2 80 80.55 100.69 100.90 0.48 0.48 
3 80 81.16 101.45       
1 160 160.86 100.53       
2 160 160.98 100.61 100.57 0.038 0.04 
3 160 160.92 100.57       
1 240 239.83 99.92       
2 240 239.51 99.79 99.85 0.069 0.07 
3 240 239.59 99.83       
 
Ruggedness 
The ruggedness of method for Valsartan and Sacubitril was 
calculated with six injections of 68μg/ml in two batches using two 
different columns. The % CV of ruggedness for sacubitril was 0.14 
with column-1 and 0.04 with column-2, and the % CV of ruggedness 
for valsartan was 0.04 with column-1 and 0.03 with column-2 (table 
7), which is within acceptance limits. 
 
Table 7: Results of ruggedness 
 Sacubitril 160μg/ml Valsartan  160μg/ml 
S. No. Column 1 Column 2 Column 1 Column 2 
1 159.06 159.12 159.18 159.14 
2 159.06 159.2 159.21 159.01 
3 159.34 159.09 159.14 159.04 
4 159.54 159.22 159.02 159.02 
5 159.15 159.11 159.15 159.09 
6 159.55 159.24 159.04 159.11 
Mean 159.28 159.16 159.12 159.06 
±SD 0.22 0.06 0.07 0.052 
% CV 0.14 0.040 0.048 0.033 
% accuracy 99.55 99.47 99.45 99.41 
 
Results of stress degradation studies 
Stress degradation studies were performed as per the ICH 
guidelinesQ1A (R2) Stability Testing of New Drug Substances and 
Products, using the proposed validated analytical method (table 10 
and 11) 
Acid degradation studies 
To 1 ml of stock solution valsartan and sacubitril, 1 ml of 2N HCl was 
added and refluxed for 30 min at 60 °c. From the above solution10 µl 
was injected into the system and the chromatograms were recorded 
to detect the stability of the sample. (fig. 2) 
 
 
Fig. 4: Chromatogram of acid degradation 
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Alkali degradation studies 
To 1 ml of stock solution of standard drug and sample valsartan and 
sacubitril, 1 ml of 2N NaOH was added and refluxed for 30 min at 60 
°c. From the above solution10 µl was injected into the system and 
the chromatograms were recorded to detect the stability of the 
sample. (fig. 5). 
Oxidative degradation 
To 1 ml of stock solution of standard drug and sample of valsartan 
and sacubitril, 1 ml of 20% H2O2was added and refluxed for 30 min 
at 60 °c. From the above solution10 µl was injected into the system 
and the chromatograms were recorded to detect the stability of 
sample (fig. 6). 
 
 
Fig. 5: Chromatogram of base degradation 
 
 
Fig. 6: Chromatogram of oxidative degradation 
 
Photostability studies 
The photochemical stability of the drug was also studied by exposing 
the 36 µg/ml solution to UV Light by keeping the beaker in UV 
Chamber for 7days or 200 Watt-hours/m2in photostability chamber. 
For HPLC study, from the above solution10 µl was injected into the 
system and the chromatograms were recorded to detect the stability 
of the sample. (fig. 7). 
 
 
Fig. 7: Chromatogram of UV degradation 
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Thermal degradation studies 
The 1 ml of stock solution of standard drug and sample of valsartan and 
sacubitril was exposed to temperature 105 °C for 24 h for HPLC study, 
from the above solution10 µl was injected into the system and the 
chromatograms were recorded to detect the stability of sample (fig. 8). 
 
 
Fig. 8: Chromatogram of thermal degradation study 
 
Table 8: Results of stress degradation studies of sacubitril 
S. No. Stress conditions Time % assay % degradation Purity angle Purity threshold 
1 Acid Degradation 30 min 91.2 8.8 0.17 0.21 
2 Base Degradation 30 min 92.6 7.4 0.16 0.22 
3 Peroxide Degradation 30 min 97.5 2.5 0.22 0.25 
4 UV Degradation 7 d 96.6 3.4 0.21 0.28 
5 Thermal Degradation 24 h 97.8 2.2 0.14 0.18 
 
Table 9: Results of stress degradation studies of valsartan 
S. No. Stress conditions Time % assay % degradation Purity angle Purity threshold 
1 Acid Degradation 30 min 97.3 2.7 0.12 0.16 
2 Base Degradation 30 min 97.1 2.9 0.19 0.25 
3 Peroxide Degradation 30 min 91.7 8.3 0.16 0.20 
4 UV Degradation 7 d 95.8 4.2 0.17 0.23 
5 Thermal degradation 24 h 98.4 1.6 0.19 0.26 
 
Valsartan and sacubitril undergoes significant degradation in acidic, 
oxidation, alkaline, and UV. Comparatively, More degradation was 
found with acid and base for sacubitril and with peroxide for 
valsartan. As per ICH guidelines peak, purity angle should be less 
than peak purity threshold. Hence, a method of the analysis of 
valsartan and sacubitril in tablet dosage form shows that the 
degradation product doesn’t interfere with the analytical 
determination. Hence the proposed analytical method is also useful 
for the determination of valsartan and sacubitril stability in a sample 
of the pharmaceutical dosage form. 
CONCLUSION 
In present study valsartan and sacubitril simultaneously 
estimated by HPLC, good linearity obtained for both drugs 
(20μg/ml-160μg/ml) with Correlation coefficient of 
0.999and0.998 for sacubitril and valsartan respectively. The 
results for precision, recovery and ruggedness were within 
limits. Hence the method was successfully applied for 
degradation studies, the developed stability indicating HPLC-UV 
method for simultaneous estimation of valsartan and sacubitril 
was novel, simple, precise, accurate, robust and cost-effective 
method. There is no HPLC method reported till now on selected 
combination drugs. Hence the developed method suitable for the 
routine analysis and quality control and percentage degradation 
of pharmaceutical preparations containing these drugs either 
individually or in combination. 
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